Immunotherapy using allo NKT cells and cells for which the α chain region of the T cell antigen receptor (TCR) gene is reconstituted into uniform Vα-Jα and banking of the cell-derived NKT cells
The present invention relates to an NKT cell obtained by in vitro differentiation of a cell in which the α chain region of the T cell antigen receptor gene is reconstituted into a uniform Vα-Jα in an NKT cell receptor-specific manner. An immunocytotherapeutic agent, comprising the allogeneic individual that does not match the genotype of at least one of the MHC loci with the NKT cell, is provided. The present invention also provides a human cell or a bank of NKT cells derived from human cells in which the α chain region of the T cell antigen receptor (TCR) gene is reconstituted into a uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prevention and / or treatment of cancer, infectious diseases, allergic diseases or autoimmune diseases.本発明は、T細胞抗原受容体遺伝子のα鎖領域がNKT細胞受容体特異的な態様で均一なVα-Jαに再構成されている細胞をin vitroで分化させることにより得られたNKT細胞を含有してなる、免疫細胞療法剤であって、該NKT細胞と、MHC遺伝子座のうち少なくとも1座のジェノタイプが一致しない同種異系個体を投与対象とする剤を提供する。また、本発明は、T細胞抗原受容体（TCR）遺伝子のα鎖領域が均一なVα-Jαに再構成されているヒト細胞または該細胞由来NKT細胞のバンクを提供する。本発明の剤や細胞バンクは、がん、感染症、アレルギー疾患または自己免疫疾患の予防および／または治療に有用である。
